Cost of hospitalization for respiratory syncytial virus chest infection and implications for passive immunization strategies in a developing nation

Acta Paediatrica, International Journal of Paediatrics

Volumn 92, Issue 4, 2003, Pages 481-485

  Chan, Patrick W K ^a   Abdel Latif, M E A ^a  

^a UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

Author keywords

Passive immunization; RSV; Treatment cost

Indexed keywords

MONOCLONAL ANTIBODY; PALIVIZUMAB; SYNARGIS;

ARTICLE; CHILD HOSPITALIZATION; CONTROLLED STUDY; COST CONTROL; DEVELOPING COUNTRY; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HEALTH CARE PLANNING; HIGH RISK POPULATION; HOSPITAL BED; HUMAN; INFANT; INFECTION RISK; INTENSIVE CARE; MAJOR CLINICAL STUDY; PASSIVE IMMUNIZATION; PRACTICE GUIDELINE; PREMATURITY; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; COST BENEFIT ANALYSIS; ECONOMICS; HOSPITAL COST; HOSPITALIZATION; LENGTH OF STAY; MALAYSIA; NEWBORN; PUBLIC HEALTH; VIRUS INFECTION;

COST SAVINGS; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; IMMUNIZATION, PASSIVE; INFANT; INFANT, NEWBORN; INTENSIVE CARE; LENGTH OF STAY; MALAYSIA; NATIONAL HEALTH PROGRAMS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; SEVERITY OF ILLNESS INDEX;

EID: 0041876241     PISSN: 08035253     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1651-2227.2003.tb00582.x     Document Type: Article

References (21)

1. Stretton M, Ajizian SA, Mitchell I, Newth CJL. Intensive care course and outcome of patients infected with respiratory syncytial virus. Pediatr Pulmonol 1992; 13: 143-50
2. Wang EEL, Law BJ, Stephens DS, Langley JM, McDonald NE, Robinson JL, et al. Pediatric Investigators' Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial virus lower respiratory tract infection. J Pediatr 1995; 126: 212-9
3. Chan PWK, Goh AYT. Respiratory syncytial virus in young Malaysian children. Sing Med J 1999; 40: 336-40
4. Heilman CA. From the National Institute of Allergy and Infectious Diseases and the World Health Organization: Respiratory syncytial virus and parainfluenza viruses. J Infect Dis 1990; 161: 402-6
5. Groothius JR, Simoes EAF, Levin MJ, Hall CB, Long CE, Rodriquez WJ, et al. Prophylactic administration of respiratory syncytial virus immunoglobulin to high-risk infants and young children. N Engl J Med 1993; 329: 1524-30
6. The PREVENT Study Group. Reduction of respiratory synyctial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997; 99: 93-9
7. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102: 531-7
8. Zempsky WT, Schechter NL. Impact-RSV study group report. Pediatrics 1999; 104: 993-4
9. American Academy of Paediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Prevention of respiratory syncytial virus infection: indications for the use of pavilizumab and update on the use of RSV-IGIV. Pediatrics 1998; 102: 1211-6
10. Chan PWK, Chew FT, Chua KB. Respiratory syncytial virus infection in Kuala Lumpur, Malaysia: is there a seasonal variation? Proc 7th Western Pacific Congr Chemother Infect Dis (WESPAC), Hong Kong, China, 2000
11. Committee on issue for New Vaccine Development. New vaccine development: establishing priorities, vol 1. Diseases of importance in the United States. Washington DC: a National Academy Press; 1985
12. Langley JM, Wang EEL, Law BJ, Stephens D, Boucher FD, Dobson S, et al. Economic evaluation of respiratory syncytial virus infection in Canadian children: a Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC). J Pediatr 1997; 131: 113-7
13. Howard TS, Hoffman LH, Stang PE, Simoes EAF. Respiratory syncytial virus pneumonia in the hospital setting: length of stay, charges and mortality. Pediatrics 2000; 137: 227-32
14. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999; 104: 419-27
15. Numa A. Outcome of respiratory syncytial virus infection and a cost-benefit analysis of prophylaxis. J Pediatr Child Health 2000; 36: 422-7
16. Thomas M, Bedford-Russell A, Sharland M. Hospitalization for RSV infection in ex-pretenn infants - implications for the use of RSV immune globulin. Arch Dis Child 2000; 122-7
17. Miedema CJ, Kors AW, Ten WET, Kimpen JLL. Medical consumption and socio-economic effects of infection with respiratory syncytial virus in the Netherlands. Pediatr Infect Dis J 2001; 20: 160-3
18. Chan PWK, Goh AYT, Lum LCS. Respiratory failure requiring ventilation in acute bronchiolitis. Med J Malaysia 1999; 54: 487-91
19. Gavin R, Anderson B, Percival T. Management of severe bronchiolitis: indications for ventilatory support. N Z Med J 1996; 109: 137-9
20. Goh AYT, Lum LCS, Chan PWK. Paediatric intensive care in Kuala Lumpur, Malaysia: a developing subspecialty. J Trop Pediatr 1999; 45: 362-4
21. Hall CB, Stevens TP, Swantz RJ, Sinkin RA, McBride JT. Development of local guidelines for prevention of respiratory syncytial virus infections. Pediatr Infect Dis J 1999; 18: 850-3